Liver transplant team involvement in level III and IV renal tumor thrombectomy: Perioperative and oncologic outcomes
In brief
Liver transplant team involvement linked to fewer major complications in kidney tumor surgery
In this single-center review of 36 operations for kidney tumors extending into major veins, major complications occurred in 11% with liver transplant team involvement versus 50% without, and hepatic dysfunction in 0% versus 39%. The groups had similar cancer survival, but the complication differences weakened after accounting for surgery year, so prospective studies are needed to clarify the team's role.
- Journal
- Urologic oncology (Q1)
- Published
- 13 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Ali H Zahalka, Bailey Brooks, Nicholas Bingham, Sofia Gereta, Solomon L Woldu, Kris Gaston, et al.
- PMID
- 43026048
- DOI
- 10.1016/j.urolonc.2026.10.010
Why clinicians should know about it
- Picked for Surgical Oncology (top studies of the week, 15 November 2026): Complex renal tumor thrombectomy outcomes and multidisciplinary surgery
Abstract
PURPOSE: Resection of renal cell carcinoma with inferior vena cava (IVC) tumor thrombus above the hepatic veins requires extensive liver mobilization using techniques derived from liver transplantation. We assessed whether dedicated liver transplant team involvement in radical nephrectomy with IVC thrombectomy for thrombi above the hepatic veins (level III and IV) was associated with perioperative and oncologic outcomes. MATERIALS AND METHODS: In this unplanned, hypothesis-generating analysis of a single-center retrospective cohort (2018-2024), cases were classified by liver transplant team involvement, and intraoperative factors, 90-day outcomes, and survival were compared. Because liver transplant team involvement was adopted progressively, sensitivity analyses adjusting for year of surgery and restricted to the adoption period were performed. RESULTS: Of 36 cases, 18 (50%) involved the liver transplant team. Intraoperative factors were similar. Liver transplant team involvement was associated with fewer major complications (Clavien grade ≥3: 11% vs. 50%, P = 0.03) and less hepatic dysfunction (0% vs. 39%, P = 0.01) within 90 days, with similar recurrence-free and overall survival. Adjusting for cardiac bypass, liver transplant team involvement was associated with lower odds of major complications (odds ratio [OR] 0.05, 95% confidence interval [CI] 0.005-0.57) and hepatic dysfunction (OR 0.04, 95% CI 0.002-0.83). After adjustment for year of surgery, point estimates were similar but neither association remained statistically significant (OR 0.13, 95% CI 0.01-1.24; OR 0.04, 95% CI 0.001-1.22). CONCLUSIONS: Liver transplant team involvement was associated with fewer major complications and less hepatic dysfunction. Although this association could not be reliably separated from calendar time, these findings warrant prospective, multi-institutional evaluation of liver transplant team involvement in high-level renal tumor thrombectomy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.